Nvidia (NVDA) Partners with Novo Nordisk to Propel AI-Driven Drug Discovery

Nvidia has announced a partnership with Novo Nordisk to enhance drug discovery through its generative and agentic AI tools. The collaboration will leverage Denmark’s Gefion supercomputer, operated by DCAI and powered by Nvidia’s DGX SuperPOD. Novo Nordisk plans to utilize Nvidia’s BioNeMo, NeMo, and NIM platforms for early research, clinical development, and biomedical modeling. The initiative focuses on creating custom AI models to improve the identification of cellular responses and expedite the development of drug-like molecules. Novo Nordisk emphasized that this advanced infrastructure will facilitate experiments at an unprecedented scale. Additionally, Gefion is being utilized by various Danish startups and health agencies to develop AI care systems and integrate national health data.

Source link